New York, New York, United States
Felix is a Principal at J.P. Morgan Life Sciences Private Capital, which he joined in June 2024. Prior to joining J.P. Morgan, Felix spent three years as a biotech investor at Arix Bioscience in London. At Arix Bioscience, Felix focused on both private and public biotechnology investments. He has led due diligence for numerous therapeutics investments and held board observer positions in several biotech companies. Felix is an immunologist and biochemist by training. He completed his PhD in biochemistry at University College London. His doctoral research at The Francis Crick Institute was supported by a Boehringer Ingelheim Fonds Fellowship and focused on innate immune pathways. Alongside his PhD, Felix was President of GapSummit 2018, the world’s first intergenerational biotech leadership forum. Felix holds a First Class Honours degree with distinction in biochemistry from the University of Dundee and published research in multiple top tier journals.
Biotech investor at J.P. Morgan Life Sciences Private Capital, focused on biotechnology investments in therapeutics. Completed deals: Ottimo Pharma, 4x Stealth Company financings, 1x NewCo
Completed deals: Disc Medicine (Nasdaq: IRON), Sorriso Pharma, Evommune (NYSE: EVMN), Ensoma, Harpoon Therapeutics (Nasdaq: HARP; acquired for $680M). Led due diligence for several therapeutics investments & have held Board Observer positions in five companies.
Biotech investor at Arix Bioscience, a global venture capital firm focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.